TN Dept of Health to Resume Administration of Johnson & Johnson COVID-19 Vaccine

Johnson & Johnson COVID-19 Vaccine Authorized For Emergency Use

After an extensive analysis of the risks and benefits of the Janssen/Johnson & Johnson COVID-19 vaccine, the Advisory Committee on Immunization Practices (ACIP) voted today to recommend to the Centers for Disease Control and Prevention (CDC) that jurisdictions may resume their administration of the Janssen/Johnson & Johnson vaccine without restrictions.

The recommendation from the ACIP is unchanged from the original recommendation provided on February 27, 2021: “The Janssen COVID-19 vaccine is recommended for persons 18 years of age and older in the U.S. population under FDA’s Emergency Use Authorization.”

The committee made the determination after reviewing cases of rare but serious blood clots occurring in some individuals who received the vaccine. To date, 15 cases have been reported with the majority occurring in women ages 18-49 years. The risk of developing the condition is approximately 7 in 1 million vaccine doses for women in that age group. For women ages 50 years and older and for men, the risk is approximately 1 in 1 million vaccines doses.

The Tennessee Department of Health is taking necessary steps to inform all approved COVID-19 vaccine providers across the state of the information released by ACIP so that they may resume the administration of the Janssen/Johnson & Johnson vaccine as soon as possible. While the Janssen/Johnson & Johnson vaccine is in short supply, most vaccine providers in Tennessee continue to have abundant supply of the Pfizer and Moderna vaccines.

“The independent review process conducted by ACIP further shows the amount of scrutiny and review that goes into ensuring the safety of all vaccines used in this country, including those that protect against COVID-19,” said Tennessee Department of Health Commissioner Lisa Piercey, MD, MBA, FAAP. “The CDC and FDA took a necessary pause in the administration of the Janssen/Johnson & Johnson vaccine and the ACIP has done its diligence to confidently recommend that the country resume its use of the vaccine. We’re excited to get this third vaccine option back into use in Tennessee.”

Women between the ages of 18 and 49 years should weigh the risk of the vaccine with its benefits when deciding to receive the Janssen/Johnson & Johnson vaccine versus the mRNA vaccines from Pfizer and Moderna, which have not been associated with this rare blood clotting disorder.

Individuals seeking a COVID-19 vaccine appointment can visit covid19.tn.gov or vaccinefinder.org to schedule an appointment with a local vaccine provider.

For more information regarding vaccine recommendations and guidelines from ACIP visit https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html.

Offers for you

Support our publication by shopping here

Soltea
Improve Your Heart Health with All-Natural Soltea Daily Supplement – Click Now to Save 25% Off Your First Order
All-Natural Heart Health Supplement – Save 25% Now
CodeMonkey
Coding for kids! Introducing programming games for the next generation. Get your kids coding today.
Start with a free trial.
Gabi
The easiest way to compare and save on home and auto insurance. Match coverage, compare rates and save.
Find hundreds in savings now!
Brigit
Know your spending habits, anticipate overdrafts, and get up to $250. Only takes 2 minutes. No credit check.
Get your finances on track.
Truebill
Lower your bills and stay on top of your financial life with Truebil, the app that helps you save every day.
Take control & start saving money!
Acorns
Acorns helps you grow your money. Take control with all-in-one investment, retirement, checking and more.
Get a $5 bonus when you sign up.
Grow Credit
Grow Credit is a free Mastercard you can use to pay your subscriptions while you build credit.
Start building your credit today!
Tally
Overcome your credit card debt with Tally. Consolidate and save money while you pay it down.
Get started with Tally today.

LEAVE A REPLY

Please enter your comment!
Please enter your name here